Pharmacogenetics of clozapine treatment response and side-effects in schizophrenia: an update

@article{Sriretnakumar2015PharmacogeneticsOC,
  title={Pharmacogenetics of clozapine treatment response and side-effects in schizophrenia: an update},
  author={V. Sriretnakumar and E. Huang and D. M{\"u}ller},
  journal={Expert Opinion on Drug Metabolism & Toxicology},
  year={2015},
  volume={11},
  pages={1709 - 1731}
}
  • V. Sriretnakumar, E. Huang, D. Müller
  • Published 2015
  • Medicine
  • Expert Opinion on Drug Metabolism & Toxicology
  • Introduction: Clozapine (CLZ) is the most effective treatment for treatment-resistant schizophrenia (SCZ) patients, with potential added benefits of reduction in suicide risk and aggression. However, CLZ is also mainly underused due to its high risk for the potentially lethal side-effect of agranulocytosis as well as weight gain and related metabolic dysregulation. Pharmacogenetics promises to enable the prediction of patient treatment response and risk of adverse effects based on patients… CONTINUE READING
    Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics
    38
    Clozapine pharmacogenomics: a review of efficacy, pharmacokinetics, and agranulocytosis
    2

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 118 REFERENCES
    Pharmacogenetics in schizophrenia: a review of clozapine studies.
    17
    Genetic variation in BDNF is associated with antipsychotic treatment resistance in patients with schizophrenia
    42
    D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis.
    165
    Clozapine: A Clinical Review of Adverse Effects and Management
    158